CDCA1-64

CDCA1-64 refers to a peptide epitope derived from the cell division cycle associated 1 (CDCA1) protein, specifically corresponding to amino acids 56–64 of the protein. This peptide is used as an immunogenic epitope in cancer immunotherapy research. The mechanism involves stimulating cytotoxic T lymphocytes (CTLs) that are specific for this HLA-A24-restricted epitope, leading to targeted immune responses against tumor cells expressing both CDCA1 and HLA-A24. Studies have shown that CTLs generated using this peptide can effectively kill cancer cells naturally expressing these markers. The broader context is the use of long peptides or short peptides derived from tumor-associated antigens like CDCA1 for therapeutic cancer vaccines or adoptive T-cell therapies[2][9]. There is no evidence that "CDCA1-64" refers to a marketed pharmaceutical product; it is primarily a research tool and candidate for experimental immunotherapies.

Other names

CDCA1-A2456–64 SPCDCA156–64CDCA1 56–64 peptide